Coloplast (COLO B) Stock Overview
Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
COLO B Community Fair Values
Create NarrativeSee what 55 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Coloplast A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 438.60 |
| 52 Week High | DKK 646.60 |
| 52 Week Low | DKK 369.70 |
| Beta | 0.55 |
| 1 Month Change | 6.51% |
| 3 Month Change | 8.67% |
| 1 Year Change | -28.80% |
| 3 Year Change | -43.77% |
| 5 Year Change | -59.96% |
| Change since IPO | 3,332.52% |
Recent News & Updates
Analysis Article • 12h
Coloplast A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
The quarterly results for Coloplast A/S ( CPH:COLO B ) were released last week, making it a good time to revisit its...
Narrative Update • Aug 19
COLO B: Biologics And China Pressures Will Restrain Sentiment Despite Guidance
Coloplast's analyst fair value estimate has moved from DKK 345 to DKK 370, reflecting updated assumptions on discount rates, margins and future P/E in the context of recent mixed price target revisions from DKK 345 to DKK 460 by various analysts. Analyst Commentary Recent Street research on Coloplast shows a mix of cautious and more constructive views on the stock's valuation and execution risks.Recent updates
Analysis Article • 12h
Coloplast A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
The quarterly results for Coloplast A/S ( CPH:COLO B ) were released last week, making it a good time to revisit its...Narrative Update • Aug 19
COLO B: Biologics And China Pressures Will Restrain Sentiment Despite Guidance
Coloplast's analyst fair value estimate has moved from DKK 345 to DKK 370, reflecting updated assumptions on discount rates, margins and future P/E in the context of recent mixed price target revisions from DKK 345 to DKK 460 by various analysts. Analyst Commentary Recent Street research on Coloplast shows a mix of cautious and more constructive views on the stock's valuation and execution risks.
Narrative Update • Jul 15
COLO B: Recent P/E Reset Will Create Upside Opportunity
Analysts have lowered the fair value estimate for Coloplast to DKK 584 from DKK 868, reflecting a reset in price assumptions and P/E expectations, while recent price targets across the Street range from DKK 345 to DKK 484. Analyst Commentary Recent Street research on Coloplast shows a wide spread in views, but there are several constructive signals that point to ongoing interest in the stock at current levels.Narrative Update • Jun 30
COLO B: Reset Expectations And New Products Will Shape Future Sentiment
The analyst price target for Coloplast has been revised from DKK 535 to DKK 345. This reflects a reset in valuation assumptions as analysts weigh recent target cuts against differing views on how the recent share selloff relates to company fundamentals and future P/E expectations.
Narrative Update • Jun 16
COLO B: Recent Pullback And New FDA Approval Will Support Future Re Rating
The analyst price target for Coloplast has been revised slightly, with the updated fair value held around DKK 462 as analysts factor in a modestly lower discount rate and only small tweaks to growth and margin assumptions following a series of recent target cuts and one new Buy initiation around DKK 482. Analyst Commentary Recent research on Coloplast highlights a split in opinion, with some analysts seeing value after the share price pullback and others focusing on execution risk and margin pressure in their updated targets.Narrative Update • Jun 02
COLO B: New CEO And Lower P/E Will Support Future Multiple Re Rating
The updated analyst price target for Coloplast moves from DKK 500.15 to DKK 461.90, as analysts factor in slightly firmer revenue growth assumptions, a small change in the discount rate, and a lower future P/E multiple, while recent research highlights both reduced targets and one new Buy initiation after the share selloff. Analyst Commentary Recent Street research on Coloplast reflects a mix of optimism and caution, with several firms adjusting price targets and ratings following the share selloff.Analysis Article • May 20
Some May Be Optimistic About Coloplast's (CPH:COLO B) Earnings
Shareholders appeared unconcerned with Coloplast A/S' ( CPH:COLO B ) lackluster earnings report last week. Our analysis...Analysis Article • May 15
Coloplast A/S Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
Last week saw the newest half-year earnings release from Coloplast A/S ( CPH:COLO B ), an important milestone in the...Narrative Update • May 10
COLO B: New CEO And Reset P/E Will Support Future Multiple Re Rating
The analyst price target on Coloplast has been reduced from DKK 551.68 to DKK 500.15, as analysts incorporate a series of recent target cuts and mixed ratings while adjusting assumptions around the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research on Coloplast has centered on a series of target cuts and rating changes that feed directly into the revised average price target.Narrative Update • Apr 24
COLO B: New CEO Appointment Will Underpin Future Multiple Re Rating Potential
Coloplast's analyst price target has been nudged lower to about DKK 552 from roughly DKK 561, reflecting recent cuts to DKK-based targets by several banks as analysts factor in a slightly higher discount rate, a modestly adjusted future P/E assumption and only small tweaks to long term growth and margin expectations. Analyst Commentary Recent Street research around Coloplast has centered on recalibrated price targets and rating changes as analysts reassess what they are willing to pay for the company, given updated discount rates and P/E assumptions.Narrative Update • Apr 09
COLO B: New CEO Appointment Will Support Future Re Rating Potential
The updated analyst price target for Coloplast has been reduced by DKK 6.53. This change reflects a slight reset in fair value as analysts incorporate higher discount rates, marginally softer margin assumptions, and recent price target cuts, along with mixed rating changes across the Street.Narrative Update • Mar 26
COLO B: New CEO Appointment And Reset P/E Will Support Future Re Rating
Coloplast's analyst fair value target has been trimmed from DKK 579.78 to DKK 567.16, as analysts factor in slightly lower long term growth, modestly softer margin assumptions and small adjustments to future P/E expectations following a mix of recent target cuts and one upgrade. Analyst Commentary Recent research on Coloplast has been mixed, with several target cuts alongside one upgrade.Narrative Update • Mar 11
COLO B: Reset P/E And New Leadership Will Support Future Re Rating
The updated analyst price target for Coloplast has been trimmed by around DKK 9 to reflect lower Street targets. This includes cuts to DKK 504 at Deutsche Bank and reductions at RBC Capital, JPMorgan and Berenberg, as analysts factor in slightly higher discount rates, modestly softer margin assumptions and a lower future P/E multiple.Narrative Update • Feb 25
COLO B: Reset P/E And Dividend Will Support Future Re Rating
Analysts have trimmed their DKK price targets on Coloplast, reflected in a lower fair value estimate from DKK 615 to DKK 588, as they factor in slightly more cautious assumptions on growth, margins and future P/E multiples following recent target reductions from several research houses. Analyst Commentary Bullish Takeaways Bullish analysts still see room for upside from current levels, even with reduced DKK price targets.Narrative Update • Feb 10
COLO B: Reset P/E And Dividend Will Support Future Upside
Analysts have trimmed their fair value estimate for Coloplast from DKK 678.22 to DKK 615.06, reflecting recent price target cuts and updated assumptions on the discount rate, revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent Street research on Coloplast has focused on recalibrating expectations rather than fundamentally changing the story.Analysis Article • Jan 25
Coloplast A/S' (CPH:COLO B) P/E Is On The Mark
Coloplast A/S' ( CPH:COLO B ) price-to-earnings (or "P/E") ratio of 33.6x might make it look like a strong sell right...Narrative Update • Jan 24
COLO B: Dividend Reliability And Premium P/E Will Support Future Upside
Analysts have lowered their Coloplast price targets by DKK 10, to a range of DKK 535 to DKK 640, reflecting slightly lower fair value assumptions, modestly softer revenue growth expectations, and a marginally reduced future P/E multiple. Analyst Commentary Recent research updates on Coloplast point to a tighter valuation range, with price targets now clustered between DKK 535 and DKK 640.Narrative Update • Jan 09
COLO B: Sustained Margins And Dividend Payouts Will Support Future Upside
Narrative update The analyst price target for Coloplast has edged up by about DKK 0.30 to reflect slightly higher fair value estimates. Recent Street research shows a mix of views, with some analysts lifting targets toward DKK 535 and others resetting them closer to DKK 640, which has led to modest adjustments to discount rate, revenue growth, profit margin, and future P/E assumptions.Narrative Update • Dec 13
COLO B: Sustained Margin Strength Will Support Upside As Dividend Payouts Increase
Analysts have nudged our Coloplast fair value estimate slightly higher to about DKK 689 per share from roughly DKK 689 previously, reflecting a modest uptick in long term multiple assumptions even as recent Street price target revisions have moved in mixed directions. Analyst Commentary Recent Street actions on Coloplast highlight a divided view on near term upside versus longer term execution and growth.Analysis Article • Dec 04
Coloplast (CPH:COLO B) Is Increasing Its Dividend To DKK18.00
Coloplast A/S ( CPH:COLO B ) has announced that it will be increasing its dividend from last year's comparable payment...Narrative Update • Nov 29
COLO B: Sustained Margin Strength Will Support Upside Amid Market Challenges
Coloplast’s analyst fair value estimate was revised slightly upward to DKK 688.67 from DKK 685.39. Analysts weighed recent price target changes along with minor adjustments to growth expectations and profit margins.Analysis Article • Nov 20
Coloplast (CPH:COLO B) Will Pay A Larger Dividend Than Last Year At DKK18.00
Coloplast A/S ( CPH:COLO B ) will increase its dividend from last year's comparable payment on the 9th of December to...Narrative Update • Nov 14
COLO B: Future Execution In Core Markets Will Drive Share Price Momentum
The analyst consensus price target for Coloplast has modestly decreased. Updated projections reflect cautious sentiment from analysts, who cite modest adjustments to growth and profitability expectations.Narrative Update • Oct 31
COLO B: Executive Team Changes And Chronic Care Strategy Will Drive Outperformance
Coloplast’s analyst price target was reduced slightly from DKK 691.83 to DKK 686.00, as analysts cite modestly lower revenue growth expectations and recent target decreases across several major firms. Analyst Commentary Recent commentary from market analysts highlights a balanced perspective on Coloplast’s outlook, with both raised and lowered price targets reflecting shifting sentiment in key performance areas.Narrative Update • Oct 17
Chronic Care Focus And Emerging Markets Will Redefine Healthcare
Coloplast's analyst price target has been reduced by nearly DKK 10 to DKK 691.83. Analysts cite mixed recent revisions in target prices, reflecting a balanced outlook amid evolving growth and margin expectations.Narrative Update • Oct 03
Chronic Care Focus And Emerging Markets Will Redefine Healthcare
Coloplast's analyst price target has been revised downward from DKK 716 to DKK 701. Analysts have adjusted their expectations in response to a series of recent target reductions following tempered growth and margin forecasts.Narrative Update • Aug 30
Chronic Care Focus And Emerging Markets Will Redefine Healthcare
Coloplast’s consensus price target was modestly reduced to DKK718.06 as analysts weighed concerns about slowing revenue growth and margin pressure against stable demand in key product portfolios and longer-term benefits from innovation and expansion. Analyst Commentary Bearish analysts cite concerns over slowing revenue growth and margin pressure, particularly in core European markets.Analysis Article • Aug 22
Coloplast A/S Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next
It's been a good week for Coloplast A/S ( CPH:COLO B ) shareholders, because the company has just released its latest...
New Narrative • Nov 07
Operational Efficiencies And Innovations In Urology And Wound Care Propel Future Growth
Improved operational efficiency and strategic expansions are expected to enhance net margins and earnings over the long term.Shareholder Returns
| COLO B | DK Medical Equipment | DK Market | |
|---|---|---|---|
| 7D | 2.4% | -0.06% | -0.05% |
| 1Y | -28.8% | -17.7% | -1.4% |
Return vs Industry: COLO B underperformed the Danish Medical Equipment industry which returned -17.7% over the past year.
Return vs Market: COLO B underperformed the Danish Market which returned -1.4% over the past year.
Price Volatility
| COLO B volatility | |
|---|---|
| COLO B Average Weekly Movement | 4.0% |
| Medical Equipment Industry Average Movement | 3.9% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in DK Market | 7.6% |
| 10% least volatile stocks in DK Market | 2.4% |
Stable Share Price: COLO B has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: COLO B's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 17,213 | Gavin Wood | www.coloplast.com |
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.
Coloplast A/S Fundamentals Summary
| COLO B fundamental statistics | |
|---|---|
| Market cap | DKK 98.13b |
| Earnings (TTM) | DKK 2.76b |
| Revenue (TTM) | DKK 28.44b |
35.7x
P/E Ratio3.5x
P/S RatioIs COLO B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COLO B income statement (TTM) | |
|---|---|
| Revenue | DKK 28.44b |
| Cost of Revenue | DKK 9.32b |
| Gross Profit | DKK 19.12b |
| Other Expenses | DKK 16.36b |
| Earnings | DKK 2.76b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Nov 03, 2026
| Earnings per share (EPS) | 12.27 |
| Gross Margin | 67.23% |
| Net Profit Margin | 9.71% |
| Debt/Equity Ratio | 170.8% |
How did COLO B perform over the long term?
See historical performance and comparisonDividends
5.2%
Current Dividend Yield188%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/21 16:38 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Coloplast A/S is covered by 42 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Hassan Al-Wakeel | Barclays |
| Robert Bate | Barclays |